Our current pipeline includes two investigational therapeutics for the treatment of cancer: evofosfamide and TH-3424.

More information about evofosfamide clinical trials may be found at ClinicalTrials.gov or by emailing the Threshold Clinical Development group at clinicaltrials@thresholdpharm.com. To learn more about our Other Assets that are currently not in development and available for licensing or acquistion, please see Tarloxotinib and our diagnostic, [18F]-HX4.